Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review.
Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review.
复制标题
DOI：
10.1016/j.lrr.2020.100206
复制
发表时间：
2020-01-01
影响因子：
--
通讯作者：
Damlaj, Moussab
中科院分区：
文献类型：
--
作者：
Abuelgasim, Khadega A;Albuhayri, Bandar;Damlaj, Moussab
急性髓系白血病(AML)的预后仍然很差。在180例患者中，中位年龄为53岁(14-88岁)。总的2年无瘤生存率分别为28.6%(+/-3.4)、47.7%(+/-6.6%)、23.6%(+/-5.8%)和11.7%(+/-4.2%)(P<；0.0001)。总的2年生存率(OS)分别为45.3%(+/-3.8%)、78.6%(+/-5.5%)、43.5%(+/-6.9%)和15.8%(+/-4.8%)(P<；0.0001)。高剂量化疗组≥61的诱导效果最好(p<；0.0001)。只有那些≤40拥有耐用的DFS和操作系统。HDC似乎能改善老年AML患者的预后。
The prognosis of acute myeloid leukemia (AML) remains poor. Among 180 patients, the median age was 53 (14-88) years. The overall 2-year disease free survival (DFS) was 28.6% (+/- 3.4), 47.7% (+/- 6.6%) for ≤ 40, 23.6% (+/- 5.8%) for 41-60 and 11.7% (+/- 4.2%) for ≥61 (p< 0.0001). The overall 2-year survival (OS) was 45.3% (+/- 3.8%), 78.6% (+/- 5.5%) for ≤40, 43.5% (+/- 6.9%) for 41-60 and 15.8% (+/- 4.8%) for ≥61 (p< 0.0001). Induction outcome of ≥61 was best in high dose chemotherapy (HDC) group (p < 0.0001). Only those ≤40 had durable DFS and OS. HDC appears to improve the outcome of older AML patients.